Kenvue Inc. is moving closer to its planned combination with Kimberly-Clark Corporation, with shareholder approvals secured and the U.S. antitrust waiting period expired, though the cash-and-stock transaction is expected to close in the fourth quarter of 2026, subject to remaining foreign regulatory approvals and customary conditions. Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash for each Kenvue share, and they are expected to own about 46% of the combined company on a fully diluted basis after closing. Kimberly-Clark has announced a post-closing organizational structure, but Kenvue is not providing forward-looking financial guidance while the deal is pending, and expected benefits may not be realized. Recent results show execution challenges: second-quarter 2026 net sales rose 3% to $3,955 million and organic sales increased 1.6%, but adjusted earnings of 31 cents per share missed the Zacks Consensus Estimate of 32 cents, while adjusted gross margin fell 70 basis points to 60.2% due to inflation, tariffs, and unfavorable transactional foreign exchange. Self Care remains a pressure point with first-half organic sales down 0.9%, while Skin Health and Beauty provided a stronger offset with organic sales up 4.4% and segment adjusted operating income rising 46.9% to $354 million. The balance sheet adds risk: Kenvue had $8.5 billion of total debt and $1.1 billion of cash as of June 28, 2026, and the 2026 restructuring program is expected to carry approximately $250 million of pre-tax charges before delivering approximately $200 million of annualized pre-tax gross cost savings. Legal and macro pressures persist, including the Second Circuit vacating the prior acetaminophen judgment in July 2026 and remanding the litigation, talc-related liabilities outside the U.S. and Canada, and annualized gross tariff exposure estimated at approximately $80 million. Major milestones are complete, but the expected fourth-quarter closing still carries regulatory, operational, and financial risk.
Kenvue Inc.Q2 adjusted EPS missed estimates, gross margin fell due to inflation, tariffs, and FX; debt and restructuring charges add risk.
Kimberly-Clark CorporationMerger nearing close with risks; deal expected to close Q4 2026, but benefits may not be realized.
Procter & Gamble Company